Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 1.85 B
The data is delayed by 15 minutes.
CBM is in the long-term up 1494% in 16 years.
Description: Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products consist of active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products. The company serves generic drug companies, and companies that discover and commercialize new small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.
|Shares Outstanding||31.98 M||EPS||2.85||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-20.81%||Sales Growth - Q/Q||-40.05%||P/E||20.14|
|P/E To EPS Growth||P/S||4.8||P/BV||7.6||Price/Cash Per Share|
|Price/Free Cash Flow||44.54||ROA||13.37%||ROE||26.34%||ROI||17.57%|
|Current Ratio||2.2||Quick Ratio||1.18||Long Term Debt/Equity||0.47||Debt Ratio||0.43|
|Gross Margin||35.31%||Operating Margin||16.19%||Net Profit Margin||16.66%||Dividend Payout Ratio|
|Cash From Financing Activities||1.6 M||Cash From Investing Activities||-12.04 M||Cash From Operating Activities||35.37 M||Gross Profit||29.08 M|
|Net Profit||7.99 M||Operating Profit||12.67 M||Total Assets||481.08 M||Total Current Assets||233.17 M|
|Total Current Liabilities||106.17 M||Total Debt||60 M||Total Liabilities||236.88 M||Total Revenue||77.53 M|
|High 52 week||68.4||Low 52 week||35.8||Last close||60||Last change||-0.25%|
|RSI||78.12||Average true range||2.66||Beta||1.21||Volume||174.76 K|
|Simple moving average 20 days||29.7%||Simple moving average 50 days||33.45%||Simple moving average 200 days||36.74%|
|Performance Week||44.89%||Performance Month||30.8%||Performance Quart||32.95%||Performance Half||52.21%|
|Performance Year||7.72%||Performance Year-to-date||58.9%||Volatility daily||8.53%||Volatility weekly||19.08%|
|Volatility monthly||39.11%||Volatility yearly||135.47%||Relative Volume||145.8%||Average Volume||405.21 K|
|New High||New Low|
2020-04-07 08:45:10 | Cambrex Completes Biopharmaceutical Expansion at its Durham, NC Facility
2020-03-13 16:25:31 | EQT, Permira, CVC Join Buyout Firms Prepping for Cash Crunch
2020-03-05 03:30:43 | Goldman Sachs’ Petershill unit in talks over minority stake in Permira
2020-03-04 05:06:36 | Permira sells into strength at remote connectivity play TeamViewer
2020-02-17 01:39:35 | Education First in exclusive talks to sell China business to Permira: sources
2020-02-13 00:15:27 | SoftBank’s got 99 problems but Sprint ain’t one
2020-02-11 20:45:29 | Permira snaps up Golden Goose sneakers in €1.3bn deal
2020-01-22 11:11:38 | Investor group to buy financial services firm Duff & Phelps for $4.2 billion
2020-01-22 02:19:44 | Permira to sell Duff & Phelps to two PE firms in $4.2bn deal
2020-01-08 14:49:50 | Lytx Reports _Largest-Ever_ Investment In Video Telematics
2020-01-08 03:23:22 | EF Education First Shortlists Bidders for Chinese Unit
2020-01-06 11:36:11 | Cambrex Announces Management Changes and Board Appointments
2019-12-04 09:27:24 | Cambrex Announces Completion of Acquisition by the Permira Funds
2019-11-18 09:30:02 | ALXN vs. CBM: Which Stock Should Value Investors Buy Now?
2019-11-14 07:30:00 | Cambrex Wins Third API Development Award at CPhI Worldwide
2019-11-04 10:35:03 | Genesis Healthcare GEN to Post Q3 Earnings: What to Expect
2019-10-31 09:30:01 | ALXN or CBM: Which Is the Better Value Stock Right Now?
2019-10-28 08:47:47 | Is Cambrex Corporation CBM A Good Stock To Buy?
2019-10-24 06:40:05 | Cambrex Releases Selected Preliminary Third Quarter 2019 Financial Results
2019-10-10 09:30:01 | ALXN vs. CBM: Which Stock Should Value Investors Buy Now?
2019-09-25 17:17:30 | Bragar Eagel & Squire, P.C. Announces that it is Investigating the Boards of Directors of Highlands, Cambrex, Two River, and Carbon Black on behalf of Stockholders and Encourages Investors to Contact the Firm
2019-09-23 06:40:00 | Cambrex Corporation Announces Expiration of “Go Shop” Period Under Merger Agreement
2019-09-17 17:33:00 | Lifshitz & Miller LLP Announces Investigation of Avedro, Inc., Cambrex Corporation, Cardinal Health, Inc., Farfetch Limited Investors, Gannett Co., Inc., Pluralsight, Inc., Textron, Inc. and Vitamin Shoppe, Inc.
2019-09-13 09:40:01 | ALXN or CBM: Which Is the Better Value Stock Right Now?
2019-09-11 20:15:50 | Bragar Eagel & Squire, P.C. Announces that it is Investigating the Boards of Directors of Cambrex, Presidio, Old Line Bancorp, and Milacron Holdings on behalf of Stockholders and Encourages Investors to Contact the Firm
2019-08-26 09:30:01 | ALXN vs. CBM: Which Stock Is the Better Value Option?
2019-08-13 17:52:00 | CAMBREX INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cambrex Corporation - CBM